Indication: Squamous Cell Carcinoma
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
Line of Therapy: Second or Third Line
Principal Investigator: Jae Jung, M.D.Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.
Email for more information: Derm-NCIResearch@nortonhealthcare.org